阿尔茨海默病及相关病2025，Vol.8Issue(2)：132-137,6.DOI:10.3969/j.issn.2096-5516.2025.02.010
β淀粉样蛋白生物标志物在阿尔茨海默病临床应用中的价值探讨
Exploring the clinical value of amyloid β-protein biomarkers in Alzheimer's disease
摘要
Abstract
Alzheimer's disease(AD)is the most common neurodegenerative disorder,characterized by the pathological hallmarks of extracellular β-amyloid plaque deposition and intracellular neurofibrillary tangles.The deposition of amyloid β-protein(Aβ)is considered the initiating and central event in the pathogenesis of AD.The study of biomarkers is important for the early diagnosis,drug development,and clinical management of AD.PET and fluid biomarkers provide unique and comprehensive information.Aβ PET can detect Aβ plaque burden and spatial distribution in the brains of AD patients,while fluid biomarkers reflect the net of rates of production/clearance of analytes at a given point in time.This review summarizes the clinical application value of Aβ PET and Aβ fluid biomarkers in the diagnosis,differential diagnosis,prognosis prediction,and therapeutic efficacy assessment of AD.关键词
阿尔茨海默病/β淀粉样蛋白/正电子发射断层扫描/体液生物标志物Key words
Alzheimer's disease/Amyloid β-protein/Positron emission tomography/Fluid biomarkers分类
临床医学引用本文复制引用
高金,卫一丹,周知,富丽萍..β淀粉样蛋白生物标志物在阿尔茨海默病临床应用中的价值探讨[J].阿尔茨海默病及相关病,2025,8(2):132-137,6.基金项目
国家自然科学基金面上项目(82071963) （82071963）
北京市自然科学基金面上项目(7242128) （7242128）
中日友好医院高水平医院临床业务费专项成果转化项目(2023-NHLHCRF-YXHZ-ZRZD-01) （2023-NHLHCRF-YXHZ-ZRZD-01）
